Literature DB >> 19451321

Safety evaluation of 1% tenofovir gel in healthy men.

J L Schwartz1, A Poindexter, A Wheeless, C K Mauck, M M Callahan.   

Abstract

This study was conducted to determine the safety of tenofovir (TFV) gel, a potential microbicide, following seven consecutive daily penile applications. Eighteen circumcised and 18 uncircumcised healthy men were randomly assigned to TFV gel versus K-Y Jelly in a 2:1 ratio within circumcision group. TFV gel or K-Y Jelly was applied onto the penis at bedtime and washed off 6-10 hours later. Safety was assessed by reported symptoms, findings and laboratory tests. Three of 24 (13%) men in the TFV group reported mild genital symptoms compared with two of 11 (18%) men in the K-Y group. Few mild genital findings were observed and no significant systemic toxicities were reported or observed. TFV gel applied to the penis for seven days was well tolerated locally and systemically and it is unlikely that male partners exposed to small amounts of TFV gel will experience significant genital or systemic toxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19451321     DOI: 10.1258/ijsa.2008.008309

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  8 in total

Review 1.  A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection.

Authors:  Tanuja N Gengiah; Cheryl Baxter; Leila E Mansoor; Ayesha Bm Kharsany; Salim S Abdool Karim
Journal:  Expert Opin Investig Drugs       Date:  2012-03-07       Impact factor: 6.206

2.  A randomized male tolerance study of dapivirine gel following multiple topical penile exposures (MTN 012/IPM 010).

Authors:  Ross D Cranston; Craig Hoesley; Alex Carballo-Diéguez; Craig W Hendrix; Marla Husnik; Lisa Levy; Wayne Hall; Lydia Soto-Torres; Annalene M Nel
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-26       Impact factor: 2.205

3.  RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.

Authors:  Peter A Anton; Ross D Cranston; Angela Kashuba; Craig W Hendrix; Namandjé N Bumpus; Nicola Richardson-Harman; Julie Elliott; Laura Janocko; Elena Khanukhova; Robert Dennis; William G Cumberland; Chuan Ju; Alex Carballo-Diéguez; Christine Mauck; Ian McGowan
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-09       Impact factor: 2.205

Review 4.  Topical microbicides and HIV prevention in the female genital tract.

Authors:  Mackenzie L Cottrell; Angela D M Kashuba
Journal:  J Clin Pharmacol       Date:  2014-03-28       Impact factor: 3.126

5.  A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel.

Authors:  Jill L Schwartz; Wes Rountree; Angela D M Kashuba; Vivian Brache; Mitchell D Creinin; Alfred Poindexter; Brian P Kearney
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

6.  First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy.

Authors:  Peter A Anton; Terry Saunders; Julie Elliott; Elena Khanukhova; Robert Dennis; Amy Adler; Galen Cortina; Karen Tanner; John Boscardin; William G Cumberland; Ying Zhou; Ana Ventuneac; Alex Carballo-Diéguez; Lorna Rabe; Timothy McCormick; Henry Gabelnick; Christine Mauck; Ian McGowan
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

7.  Multicompartmental Pharmacokinetic Model of Tenofovir Delivery to the Rectal Mucosa by an Enema.

Authors:  Yajing Gao; David F Katz
Journal:  PLoS One       Date:  2017-01-23       Impact factor: 3.240

8.  Abolishing HIV-1 infectivity using a polypurine tract-specific G-quadruplex-forming oligonucleotide.

Authors:  Maike Voges; Carola Schneider; Malte Sinn; Jörg S Hartig; Rudolph Reimer; Joachim Hauber; Karin Moelling
Journal:  BMC Infect Dis       Date:  2016-07-22       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.